Drug Company Shamed Into Giving 7-Year-Old Life-Saving Medication

Chimerix, a North Carolina drug company refused to sell a potentially life-saving drug to a seven-year-old fighting cancer.


Chimerix, a North Carolina drug company initially refused a potentially life-saving drug to a 7 year-old with cancer, because it could delay the drug's eventual FDA approval. Only after immense public pressure did Chimerix relent and allow the child's parents to purchase the drug.

Now before you start pointing fingers, back it up a bit. There’s such a thing known as “benefit of the doubt” which ought to be exercised.

Chimerix may have had a legitimate reason for initially denying the treatment.

Seven-year-old Josh Hardy has survived multiple kidney cancer and heart failure in the past. Unfortunately, he caught a virus in January that caused heart and kidney failure and he vomited blood several times a day.

The young boy’s doctors suggested an unapproved anti-viral drug ‘brincidofovir’ could save his life. His parents petitioned for the drug immediately .

The president of Chimerix instantly acknowledged the petition, sympathizing with the parents. However, they had to take into account the probability that the unapproved drug could lead to side effects which would delay the FDA’s decision in putting in out in the market.

The way I see it, this drug was not tested enough and if god forbid, things go wrong, it could put off a potentially beneficial drug from reaching many cancer patients like young Josh.

Chimerix Vs Josh Hardy


Josh  Hardy


Josh told CNN “Chimerix wouldn't help Josh because of the high cost”


Max Cure Foundation- a pediatric cancer charity offered to cover the cost which Chimerix President Kenneth Moch rejected for ethical reasons.


U.S. Food and Drug Administration (FDA) has not approved of the drug.


U.S. Food and Drug Administration (FDA) also offers compassionate care exception/expanded access which "allows patients with serious or life-threatening diseases who have exhausted currently available treatment options to access experimental drugs outside of clinical trials."

Eventually, the pharmaceutical company gave in, making an exception. "I'm happy for Josh and I'm happy for many patients," Moch told CNN. He added, "We've come up with a way of helping not just Josh, but helping other patients in need, and there are many."